Tmunity Therapeutics
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
$10.0m | Series A | ||
$100m | Series A | ||
$35.0m | Series A | ||
* | $75.0m | Series B | |
* | N/A | Acquisition | |
Total Funding | CAD300m |
Related Content
Recent News about Tmunity Therapeutics
EditTmunity Therapeutics is a private biotherapeutics company headquartered in Philadelphia, specializing in next-generation T cell immunotherapy. The company focuses on developing personalized immunotherapies for cancer, infectious diseases, and autoimmune diseases. Tmunity leverages broad collaborations with the University of Pennsylvania (UPenn) and the University of Minnesota, utilizing their laboratories and production facilities, alongside its own dedicated resources. The company serves patients suffering from devastating diseases, aiming to save and improve lives through innovative treatments. Tmunity's business model revolves around advancing its proprietary immunotherapies through clinical trials, with the goal of bringing these therapies to market. Revenue is generated through successful clinical trials, partnerships, and potential future commercialization of its therapies.
Keywords: T cell immunotherapy, personalized medicine, cancer treatment, infectious diseases, autoimmune diseases, clinical trials, biotherapeutics, UPenn collaboration, innovative treatments, Philadelphia.